FDA Extends Patent Review for ELAHERE Drug
Published Date: 5/19/2025
Notice
Summary
The FDA has officially set the review period for ELAHERE, a human biological product, so its patent can be extended. This means the company behind ELAHERE gets more time to protect their invention and keep competitors at bay. If you’re in the business of making or selling similar products, this update could affect when new versions hit the market and how long the original patent lasts.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Patent Extension Determination for ELAHERE
The FDA has determined the regulatory review period for ELAHERE, a human biological product, which enables the product’s patent to be extended. This gives the company behind ELAHERE more time to protect its invention and keep competitors out of the market.
Possible Market Delays for Competing Products
If you make or sell products similar to ELAHERE, this FDA determination could delay when your competing product reaches the market because the ELAHERE patent can be extended. That may keep the original product exclusive for longer and affect your product launch timing.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2025-08852, Self-Regulatory Organizations; NYSE Texas, Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Adopt Rule 7.35 and Amend Rule 7.31
NYSE Texas is rolling out a new Rule 7.35 to make auctions smoother and updating Rule 7.31 to add cool new order types like Imbalance Offset Orders and Q Orders. These changes affect traders and market makers by improving how trades happen, especially for certain Exchange Traded Products. The new rules kicked in right away on May 9, 2025, aiming to boost trading efficiency without extra costs.
Next: 2025-08856, Colorado River Basin Salinity Control Advisory Council Notice of Public Meeting
The Colorado River Basin Salinity Control Advisory Council is holding a public meeting to talk about keeping the river water clean and salty-free. This affects farmers, communities, and anyone who relies on the river for water. The meeting will share updates on plans and funding to help protect this important water source.